EC approves AbbVie's Venclexta in combination with Rituxan for CLL

The European Commission approved Venclyxto venetoclax in combination with Rituxan rituximab to treat relapsed/refractory chronic lymphocytic leukemia in patients who have received at least one prior therapy. Venclyxto is already approved for the indication as a monotherapy in the EU.

The approval was based on the Phase III MURANO trial, which showed that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda bendamustine plus Rituxan...